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Background: We conducted a phase I trial to determine the safety of systemic che-
motherapy prior to abdominopelvic robotic stereotactic ablative radiotherapy (SABR) in 
women with persistent or recurrent gynecologic cancers.
Methods: Patients were assigned to dose-finding cohorts of day 1 carboplatin (AUC 2 or 4) 
and gemcitabine (600 or 800 mg/m2) followed by day 2 to day 4 Cyberknife SABR (8 Gy × three 
consecutive daily doses). Toxicities were graded prospectively by common terminology criteria 
for adverse events, version 4.0. SABR target and best overall treatment responses were 
recorded according to response evaluation criteria in solid tumors, version 1.1.
Findings: The maximum tolerated dose of chemotherapy preceding SABR was carboplatin 
AUC 4 and gemcitabine 600 mg/m2. One patient experienced manageable, dose-limiting 
grade 4 neutropenia, grade 4 hypokalemia, and grade 3 nausea attributed to study 
treatment. One patient had a late grade 3 rectovaginal fistula 16 months after trial therapy. 
Among 28 SABR targets, 22 (79%) showed a partial response and 6 (21%) remained stable.
interpretation: Systemic chemotherapy may be given safely prior to abdominopelvic 
robotic SABR with further investigation warranted.
Keywords: stereotactic radiosurgery, radiation, carboplatin, gemcitabine, ovarian cancer, endometrial cancer, 
cervix cancer
introduction
Ovarian, uterine, cervix, and vulvar cancers that recur or persist after initial treatment pose 
therapeutic management challenges. As many as 4 of every 10 women with recurrent or persistent 
gynecologic cancers have disease sites that abut organs that may have been previously taxed by 
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chemotherapy or radiation, narrowly limiting clinically benefi-
cial treatment options (1–3). In an effort to work around limits 
imposed by any prior treatment-related morbidity, investigators 
have explored whether stereotactic ablative radiotherapy (SABR) 
can be used safely and effectively as a non-invasive radiation 
treatment for women with abdominopelvic sites of recurrent 
or persistent gynecologic cancers (1–14). One phase II clinical 
trial indicated that a SABR-targeted gynecologic cancer disease 
control rate could be as high as 96% (1). But, in that same trial, 
it was noted that 62% of the SABR-treated patients had eventual 
non-SABR-targeted elsewhere disease progression (1). Whether 
a safe approach incorporating SABR and systemic chemotherapy 
could address both local and regional/distant gynecologic cancer 
disease has not been explored until now.
The rationale for this clinical trial was twofold. This first-ever 
SABR radiochemotherapy phase I trial evaluated safety concerns 
for the concurrent back-to-back administration of chemotherapy 
and high-dose radiation. By building upon an already characterized 
SABR dose of 24 Gy delivered in three consecutive daily doses of 8 Gy 
(1), we evaluated dose-escalated single intravenous administrations 
of carboplatin and gemcitabine chemotherapy administered before 
SABR for the purpose of early toxicity assessment of the back-to-back 
therapy. SABR was delivered by a robot-mounted linear accelerator 
[Cyberknife®, Accuray (Sunnyvale, CA, USA)] that enabled real-time 
cancer-target motion management and submillimeter radiation target 
accuracy. Carboplatin was selected for its DNA-damaging cytotoxicity 
and its relatively low-adverse event profile when compared to cisplatin 
(15, 16). Gemcitabine was selected for its inhibition of ribonucleotide 
reductase (RNRi) and its modest single-agent adverse event rate (17, 
18). The second trial rationale addressed a clinical need for improved 
non-SABR targeted elsewhere disease control. Platinum-RNRi agent 
doublets range in activity from 16% in platinum-resistant recurrent 
ovarian cancer (19) to 50% in recurrent endometrial cancer (20). By 
studying back-to-back administration of chemotherapy and high-dose 
radiation, investigators had the opportunity to study clinical impact 
upon near-term tolerance of post-trial chemotherapy. Altogether, 
our objective was to identify a safe dose of carboplatin–gemcitabine 
chemotherapy preceding SABR – establishing a proof-in-concept 
that systemic chemotherapy may be administered safely before an 
ablative radiation course.
Materials and Methods
This phase I single-center trial (NCT01652794) enrolled 12 
patients between June, 2012, and March, 2014 to a regimen of 
dose-escalated carboplatin and gemcitabine chemotherapy given 
1  day prior to 3  days of abdominopelvic robotic SABR for the 
treatment of recurrent or persistent gynecologic cancers (Table 1).
Patients
All enrolled patients provided written informed consent and ful-
filled the following criteria were 18 years or older, had one and up to 
four measurable sites of disease as defined by Response Evaluation 
Criteria in Solid Tumors (RECIST) version 1.1, had disease sites 
that had not undergone prior cryosurgery, radiofrequency abla-
tion, or radiosurgery (although they may have had radiosurgery to 
another non-target disease site), had a performance status of 0 or 1, 
TaBle 1 | Patient and tumor characteristics (n = 12).
characteristic no. of patients %a
Age group
 40–49 1 8
 50–59 3 25
 60–69 7 58
 70–79 1 8
Race
 White 9 75
 Black or African-American 3 25
Ethnicity
 Hispanic 0 0
 Non-Hispanic 12 100
Ecog performance statusb
 0 7 58
 1 5 42
Histology
 Primary peritoneal cancer 1 8
 Ovarian cancer 7 58
 Uterine cancer 4 33
Number of radiosurgery targets
 1 3 25
 2 3 25
 3 5 42
 4 1 8
Radiosurgery targets
 Abdominal lymph node 7 58
 Liver 3 25
 Vagina 2 17
Pretherapy sum longest dimension
 0–5 cm 4 33
 5.1–10 cm 3 25
 10.1–15 cm 3 25
 15.1–20 cm 2 17
aMay not total 100 due to rounding. 
bThe Eastern Cooperative Group (ECOG) performance status reflects individual daily 
living activities on a scale of 0 (fully active with symptoms) to 5 (dead).
and had no severe congestive heart failure, angina, cardiac arrhyth-
mia, uncontrolled hypertension, dyspnea at rest, renal function 
impairment (i.e., creatinine >2.0), or psychiatric illness. Patients 
also must have had at least one systemic chemotherapy regimen 
directed at recurrent or persistent gynecologic cancer, must be 
recovered from systemic chemotherapy for more than 28 days, 
and must have had any prior chemotherapy treatment-related 
toxicities resolve to less than or equal to grade 1. Patients must 
have had adequate organ function including absolute neutrophil 
count >1,500/mcl, platelets >100,000/mcl, hemoglobin ≥10 mg/
dl, creatinine ≤2.0 mg/dl, bilirubin ≤1.5 × upper limit of normal 
(ULN), and aspartate aminotransferase, alanine aminotrans-
ferase, and alkaline phosphatase ≤2.5 × ULN. Exclusion criteria 
included pregnant women, patients with known anaphylaxis to 
carboplatin or to gemcitabine chemotherapy, patients with active 
lupus, dermatomyositis, Crohn’s disease, or ulcerative colitis, 
patients with human immunodeficiency virus actively taking 
antiretroviral therapy, patients with transplanted organs at-risk 
for lethal dysfunction or infection, patients with active non-
gynecologic invasive malignancy (except treated non-melanoma 
TaBle 2 | critical organ radiation dose constraints table.
Organ Total dose constraint 1 Total dose constraint 2 α/β ratio
Spinal cord 95% <18 Gy Not more than 0.3 cc >20 Gy 2.5
Liver 67% <17 Gy Not more than 700 cc <15 Gy 2.5
Heart 95% <15 Gy 60% <15 Gy 3.0
Partial right lung 95% <12 Gy 60% <8 Gy 4.0
Partial left lung 95% <12 Gy 60% <8 Gy 4.0
Both lung 95% <12 Gy 60% <8 Gy 4.0
Partial right kidney 90% <14 Gy 50% <10 Gy 2.4
Partial left kidney 90% <14 Gy 50% <10 Gy 2.4
Both kidney 90% <14 Gy 50% <10 Gy 2.4
Bladder 90% <24 Gy 60% <12 Gy 7.8
Rectum 90% <24 Gy 60% <10 Gy 3.0
Small bowela Not more than 1 cc >24 Gy N/A N/A 8.4
Right femoral head 90% <20 Gy 50% <15 Gy 3.0
Left femoral head 90% <20 Gy 50% <15 Gy 3.0
Skin 95% <24 Gy 50% <12 Gy 10.5
aIncludes stomach. 
cc, cubic centimeters; N/A, not applicable.
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skin cancer) within the previous 2 years, and patients with any 
history or evidence of active central nervous system disease [i.e., 
primary brain tumor, uncontrolled seizures, brain metastases, or 
cerebrovascular accident (stroke), transient ischemic attack (TIA), 
or subarachnoid hemorrhage]. University Hospitals of Cleveland 
and Case Western Reserve University (Cleveland, OH, USA) 
Institutional Review Board approval was granted for this phase 
I trial. The Case Comprehensive Cancer Center Data Safety and 
Toxicity Committee of University Hospitals of Cleveland and Case 
Western Reserve University provided oversight for this trial.
Protocol Treatment
This was a dose-finding phase I study of carboplatin and gem-
citabine chemotherapy in combination with abdominopelvic 
robotic SABR. Carboplatin was obtained commercially and was 
administered as a 30-min continuous infusion for desired exposure 
(AUC) as determined by the Calvert formula (21). Gemcitabine 
was obtained commercially and was administered as a 30-min 
continuous infusion. A Fibonacci 3 + 3 cohort trial design was 
implemented for carboplatin–gemcitabine dose-escalation levels 
of AUC 2–600 mg/m2, AUC 4–600 mg/m2, and AUC 4–800 mg/
m2, respectively. A single observed dose-limiting toxicity (DLT) 
event would lead to an additional three patients being treated at the 
dose level where the DLT occurred. Dose-finding escalation would 
continue if no additional DTLs were observed. Two observed 
DLTs would stop dose escalation, with the prior dose level being 
declared the maximum tolerated dose as long as six patients had 
been treated with less than one instance of DLT.
Stereotactic ablative radiotherapy involved three consecutive daily 
fractions of 8 Gy/fraction totaling 24 Gy using the robotic Cyberknife 
radiosurgery platform (Accuray). The robot arm-mounted linear 
accelerator delivered 6 MV radiation beams collimated by a tungsten-
copper alloy iris aperture (1, 6). Gold fiducials or bony landmarks 
were used for image guidance during SABR dose delivery. SABR 
planning involved same-day thorax to mid-thigh non-contrasted 
contiguous axial 2-[18F] fluoro-2-deoxy-d-glucose positron emission 
tomography scans (FDG PET) and axial computed tomography or 
magnetic resonance imaging scans acquired in the head-first supine 
position following institutional protocol (22). FDG PET images were 
processed and co-registered for inverse radiation treatment planning 
using the MultiPlan 3.5.2 treatment planning system (Accuray). The 
clinical target volume (CTV) included the gross gynecologic cancer 
tumor volume (GTV) and any associated FDG PET signal extending 
around the GTV [i.e., thresholded 40% maximum target standard 
uptake value (22)]. A 3-mm margin was added to the CTV for a plan-
ning tumor volume (PTV). No more than four intended SABR targets 
could be treated on trial. An individual SABR target lesion volume 
could not exceed 160  cm3. Normal tissue contours were applied 
following convention – a peer-reviewed, video-complemented 
method for robotic SABR offers further specifics (6). Table 2 lists 
SABR radiation dose constraints.
safety assessments and Follow-Up
Patients had physical examinations and baseline hematological, 
hepatic, and renal function blood tests, baseline adverse event assess-
ments [National Cancer Institute Common Terminology Criteria for 
Adverse Events (CTCAE), version 4.0], and baseline FDG PET scans 
within 35 days before the start of treatment. Hematological, hepatic, 
and renal function blood tests were repeated on days 8, 22, and 
42. Platelet level and complete blood counts with differential were 
repeated on day 15. Posttherapy physical examinations and CTCAE 
adverse event assessments were repeated on day 42. Posttherapy 
FDG PET scans were mandatory and obtained on day 42 ± 5 days. 
Patients were considered “off-trial” after day 42, but patients were 
followed generally every 3 months thereafter by one of the treat-
ing physicians. Table 3 identifies protocol-defined adverse events 
occurring during therapy or within the first 6 weeks posttherapy.
evaluation of clinical activity and statistical 
Methods
Stereotactic ablative radiotherapy target responses were recorded 
following RECIST (23). SABR target FDG PET metabolic responses 
were assessed using previously outlined criteria (24, 25). Briefly, 
a complete metabolic response was absence of abnormal SABR 
TaBle 3 | adverse events by grade with any relationship to protocol 
treatment (n = 12).
Toxicity grade
1 2 3 4 5
no. no. no. no. no.
Blood/anemia 4 2 0 0 0
Constitutional (general) 0 0 0 0 0
 Administration site pain 0 1 0 0 0
 Anaphylaxis 0 0 1 0 0
 Fatigue 9 3 0 0 0
Dermatology/skin 2 0 0 0 0
Gastrointestinal (general) 0 0 0 0 0
 Abdominal pain 1 0 0 0 0
 Constipation 2 0 0 0 0
 Diarrhea 4 2 0 0 0
 Dyspepsia 0 1 0 0 0
 Emesis 2 0 0 0 0
 Nausea 8 1 1 0 0
Infection (any site) 1 2 0 0 0
Investigations (general) 1 0 0 0 0
 Alkaline phosphatase increased 2 0 0 0 0
 Aspartate aminotransferase increased 2 0 0 0 0
 Neutrophil count decreased 6 3 1 1 0
 Platelet count decreased 12 2 1 0 0
 White blood cell decreased 11 4 2 0 0
Metabolic/nutrition (general) 0 0 0 0 0
 Anorexia 1 0 0 0 0
 Dehydration 0 1 0 0 0
 Hyperglycemia 1 0 0 0 0
 Hyperkalemia 1 0 2 0 0
 Hypoalbuminemia 3 1 0 0 0
 Hypocalcemia 1 1 0 0 0
 Hypoglycemia 1 0 0 0 0
 Hypokalemia 1 0 2 1 0
 Hypomagnesemia 2 0 0 0 0
Neurology 4 0 0 0 0
Pulmonary 1 0 0 0 0
Psychiatric (depression/insomnia) 1 0 0 0 0
Renal/genitourinary 0 0 0 0 0
Sexual/reproductive function 1 0 0 0 0
Totals 85 24 10 2 0
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target FDG uptake above cardiac blood pool FDG uptake. A partial 
metabolic response was a 15% or more reduction in abnormal 
SABR target FDG uptake. Stable metabolic response was recorded 
when there was a 25% or less increase or <15% reduction in SABR 
target FDG uptake. Progressive metabolic disease response was 
defined as a >25% increase in SABR target FDG uptake. Local 
disease relapse was recorded as disease progression of in-field 
SABR target(s). Elsewhere distant disease relapse was scored as 
any progression of disease out-of-field from SABR target(s). Time 
at-risk for disease progression or death was measured from the first 
date of trial carboplatin–gemcitabine chemotherapy until the date 
of the event. Descriptive and graphical statistics were computed 
using statistical software (SPSS 18.0, SPSS Inc., Chicago, IL, USA).
results
Patients
Twelve patients underwent dose-escalated carboplatin–gemcit-
abine chemotherapy prior to abdominopelvic robotic SABR for the 
treatment of recurrent or persistent gynecologic cancers (Tables 1 
and 2). All 12 (100%) received their prescribed carboplatin and 
gemcitabine infusions, all 3 prescribed SABR radiation treatments, 
and all are included in the treatment safety analysis. As of the date 
of data cutoff (March 12, 2015), all patients have been followed 
for >6-week on-trial period. The median follow-up is 21 months 
(range, 5–31 months).
Patients with recurrent or persistent ovarian (58%), uterine 
(33%), or primary peritoneal (8%) cancers were enrolled on this trial 
(Table 1). All patients had received prior chemotherapy for recurrent 
or persistent disease before carboplatin–gemcitabine–SABR treat-
ment. Prior to trial enrollment, five (42%) had had prior conventional 
pelvic radiation and two (17%) had SABR to elsewhere sites of 
disease. On this trial, three patients received SABR within their prior 
conventional pelvic radiation fields. Patient pretherapy SABR target 
parameters are listed in Table 1. SABR treatment targeted lymph 
node sites of disease (including para-aortic, pelvic, or groin nodes) 
in 7 (58%) of the 12 patients. The median SABR target size (i.e., 
sum volume of all SABR targets up to four lesions, no individual 
lesion >160 cm3) was 72 cm3 (range, 7–248 cm3). Nine (75%) patients 
received adjuvant therapy following SABR, including chemotherapy 
or hormonal therapy starting after the 6-week trial period.
safety and Tolerability
Twelve patients received 12 (100%) planned intravenous doses 
of carboplatin and gemcitabine chemotherapy on day 1 prior to 
day 2 to day 4 SABR treatments. Both 30-min infusions were well 
tolerated at all drug dose-escalation levels, with a single revers-
ible hypersensitivity reaction to infusion occurring on day 1 in 
one patient. This patient was aggressively supported, medicated, 
and re-challenged such that both chemotherapy infusions were 
administered without subsequent incident.
Adverse events attributed to carboplatin–gemcitabine–SABR 
treatment are listed in Table 3. Most (97%) carboplatin–gemcitabine 
drug-related adverse events were mild to moderate in intensity 
(i.e., grade ≤3, resolving to grade 0–2 within 2 days). Two grade 4 
dose-limiting toxicities, one each of hypokalemia and neutropenia, 
occurred in a single patient enrolled to the carboplatin AUC 4 and 
gemcitabine 600 mg/m2 dose level. This one patient was hospitalized 
on day 8 for these toxicities. The patient improved with supportive 
care and recovered to baseline function 1 day later. A total of five 
other patients at the carboplatin AUC 4 and gemcitabine 600 mg/
m2 dose level had no dose-limiting toxicities. After dose escalation 
to carboplatin AUC 4 and gemcitabine 800 mg/m2, one diabetic 
patient had a single reversible grade 3 hyperglycemia event pos-
sibly related to treatments. Another patient at this dose level had 
a single reversible grade 3 neutropenia event possibly related to 
treatments. The phase I data safety and monitoring committee 
elected to stop carboplatin–gemcitabine dose administration at 
the AUC 4–800 mg/m2 level after three patients had been treated, 
and declared the AUC 4–600 mg/m2 level the maximum tolerated 
dose since six patients had been treated at that dose level with only 
a single DLT being observed. One patient, who was treated at the 
carboplatin AUC 4 and gemcitabine 600 mg/m2 level along with 
SABR directed at a rectovaginal recurrence (pretreatment volume 
80 cm3) and who had prior surgery but no prior radiation therapy, 
developed a possibly treatment-related late rectovaginal fistula 
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16 months after trial therapy requiring a diverting colostomy. No 
carboplatin–gemcitabine–SABR treatment-related deaths occurred.
clinical activity
Among the 12 patients, carboplatin–gemcitabine–SABR con-
trolled all targeted disease at 6 weeks posttherapy, with 22 (79%) 
targets labeled as partial responses and 6 (21%) targets labeled 
stable responses. A 6-week metabolic partial response (i.e., >15% 
decrease in target FDG SUVmax) was achieved in 8 (67%) patients. 
The median decrease in FDG SUVmax was 39% (range, +6 to −76%). 
No local in-field SABR target disease progression has been recorded 
in the 6-week trial period. Disease progression outside of the SABR 
field occurred in nine (75%) patients, six of whom had received 
additional hormonal therapy or chemotherapy after the 6-week 
carboplatin–gemcitabine–SABR trial period. Four (33%) patients 
had a disease progression date more than 6 months after the start 
of carboplatin–gemcitabine–SABR treatment. Three of these four 
patients received additional post-trial chemotherapy. One patient 
with recurrent ovarian cancer has had a progression-free interval 
of 27 months. Two patients with recurrent uterine cancer have had 
progression-free intervals of 16 and 27 months.
Discussion
Most gynecologic cancers are sensitive to radiochemotherapy 
with initial response rates exceeding 80% following surgery, 
chemotherapy, radiation, or a combination of these treatments. 
However, recurrent or persistent disease after initial anticancer 
intervention remains a substantial hurdle in the long-term control 
of these diseases. In women with recurrent or persistent gynecologic 
cancers, SABR has yielded good local control and a well-tolerated 
toxicity profile (1). But one major drawback of a SABR therapeutic 
strategy is its inability to target disease not discernable on diagnostic 
imaging. This phase I trial determined the maximum tolerated doses 
of carboplatin to be an AUC of 4 and gemcitabine to be 600 mg/
m2 prior to three-fraction daily 8 Gy SABR treatments in a heavily 
pretreated population of patients. Although our selection of initial 
single-administration carboplatin–gemcitabine dose levels appeared 
to be conservative, hematological, and electrolyte toxicity did not 
allow for full dose escalation. Toxicity emerged typically by the sec-
ond week after treatment, with one patient requiring hospitalization 
on day 8. Carboplatin AUC 4 and gemcitabine 600 mg/m2 doses were 
administered safely, but treatment was still associated commonly 
with hematological and electrolyte abnormalities in the 6-week 
posttherapy observation period. A longer observation period for 
late posttherapy toxicities would strengthen this study.
The concept of systemic and radiosensitizing chemotherapy 
administered prior to SABR for the treatment of recurrent or 
persistent gynecologic cancer does not have precedent. In this trial, 
carboplatin and gemcitabine were selected purposefully for their 
known clinical anticancer activity and their known tolerable safety 
profile. While it is difficult to determine whether anticipated systemic 
and radiobiological effects occurred in SABR and occult non-SABR 
targets, it is encouraging to find that carboplatin–gemcitabine–SABR 
did result in four (33%) patients having a disease progression date of 
more than 6 months posttherapy. But, three of these patients received 
at least one additional cycle of chemotherapy, and thus the results 
cannot be attributed to trial therapy alone. It is important to point out 
that our study was not designed to have sufficient power to comment 
upon important outcome differences among the enrolled patients. In 
one of our exploratory analyses, we found that eight (67%) patients 
achieved a metabolic partial response (i.e., >−15% reduction in SUV). 
Nevertheless, the greatest absolute reductions in FDG standard uptake 
value did not match the longest disease-free intervals. A more rigor-
ous study of tumor FDG uptake heterogeneity and kinetics, a more 
homogenous patient cohort, and more uniform adjuvant manage-
ment after the 6-week trial period would have strengthened our study.
There are exciting opportunities for implementing combined 
systemic chemotherapy and SABR in women with recurrent or 
persistent gynecologic cancers. Clinical experience now suggests 
that gynecologic cancers that at first might have been considered 
refractory to chemotherapy or to radiation ultimately may be 
sensitive to SABR (1). With improvements in systemic and biologic 
chemotherapies that improve efficacy and lower chemotherapy-
related adverse events, combined systemic chemotherapy and 
SABR may serve as a safe therapeutic modality for women with 
recurrent or persistent gynecologic cancers. Translational clinical 
trial evaluations of optimally timed and sequenced chemotherapy 
and SABR are of considerable interest to meet therapeutic needs of 
women with recurrent or persistent gynecologic cancers.
research in context
Systematic Review
Our manuscript reports, for the first time, systemic chemotherapy 
combined with abdominopelvic robotic stereotactic radiosurgery for 
the treatment of women with recurrent or persistent gynecologic 
cancers. We searched PubMed with the terms “chemotherapy,” 
“radiosurgery,” “gynecologic cancer,” and “clinical trial” for pub-
lications between January 1, 1999, and March 12, 2015. Only the 
original single institution robotic stereotactic body radiosurgery 
phase II trial was found (1). We broadened our publication 
search and identified three review articles (26–28). These three 
publications and their referent radiosurgery publications (2–5, 
7–14) were selected to frame the context of our phase I trial data.
Interpretation
Carboplatin–gemcitabine–SABR treatment in women with 
recurrent or persistent gynecologic cancer demonstrates safety 
results that warrant further chemotherapy–SABR evaluations. 
Chemotherapy–SABR trials combining upfront radiochemo-
therapy followed by maintenance chemotherapy may be most 
desirable to lengthen clinical benefit.
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